Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors

Abstract Background Imatinib shows limited efficacy in patients with gastrointestinal stromal tumors (GISTs) carrying secondary KIT mutations. HQP1351, an orally bioavailable multikinase BCR-ABL inhibitor, is currently in clinical trials for the treatment of T315I mutant chronic myelogenous leukemia...

Full description

Bibliographic Details
Main Authors: Xuechao Liu, Guangfeng Wang, Xianglei Yan, Haibo Qiu, Ping Min, Miaoyi Wu, Chunyang Tang, Fei Zhang, Qiuqiong Tang, Saijie Zhu, Miaozhen Qiu, Wei Zhuang, Douglas D. Fang, Zhiwei Zhou, Dajun Yang, Yifan Zhai
Format: Article
Language:English
Published: BMC 2019-10-01
Series:Cell & Bioscience
Subjects:
Gastrointestinal stromal tumor
Drug resistance
Kit tyrosine kinase
Imatinib
Online Access:http://link.springer.com/article/10.1186/s13578-019-0351-6

Internet

http://link.springer.com/article/10.1186/s13578-019-0351-6

Similar Items